Get the Stockscreener App
2.82
2.55%
0.07
After Hours:
2.84
0.02
+0.71%
Esperion Therapeutics Inc stock is traded at $2.82, with a volume of 4.32M.
It is up +2.55% in the last 24 hours and up +6.02% over the past month.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
See More
Previous Close:
$2.75
Open:
$2.78
24h Volume:
4.32M
Relative Volume:
0.63
Market Cap:
$568.58M
Revenue:
$116.33M
Net Income/Loss:
$-209.25M
P/E Ratio:
-1.3302
EPS:
-2.12
Net Cash Flow:
$-135.49M
1W Performance:
+3.68%
1M Performance:
+6.02%
6M Performance:
+196.84%
1Y Performance:
+38.24%
1-Day Range:
$2.71
$2.85
1-Week Range:
$2.515
$2.85
52-Week Range:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Name
Esperion Therapeutics Inc
Sector
Phone
734-887-3903
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.82 | 636.96M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
145.06 | 63.85B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.08 | 44.34B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.41 | 42.21B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.42 | 22.15B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
432.69 | 19.60B | 3.08B | 1.24B | 1.07B | 25.61 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-24 | Initiated | Goldman | Neutral |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-20-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-01-23 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Jun-15-23 | Upgrade | BofA Securities | Underperform → Buy |
| Mar-16-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-16-23 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Mar-07-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-27-23 | Resumed | BofA Securities | Neutral |
| Feb-24-23 | Upgrade | Jefferies | Hold → Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-05-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-10-22 | Initiated | H.C. Wainwright | Buy |
| Oct-19-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-14-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-05-21 | Downgrade | Stifel | Buy → Hold |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-12-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-21 | Downgrade | Goldman | Neutral → Sell |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-29-20 | Resumed | JP Morgan | Underweight |
| Aug-11-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-01-20 | Resumed | BofA/Merrill | Buy |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-24-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-16-19 | Upgrade | Goldman | Sell → Neutral |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-06-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Apr-26-19 | Upgrade | Goldman | Sell → Neutral |
| Mar-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-07-19 | Reiterated | Needham | Strong Buy |
| Dec-13-18 | Initiated | Goldman | Sell |
| Oct-29-18 | Upgrade | Northland Capital | Market Perform → Outperform |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Aug-17-18 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-03-18 | Downgrade | JP Morgan | Neutral → Underweight |
| May-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
View All
Esperion Therapeutics Inc Stock (ESPR) Latest News
Can Esperion Therapeutics Inc. stock reach $100 price targetSell Signal & Daily Volume Surge Trade Alerts - newser.com
Will Esperion Therapeutics Inc. (0ET) stock benefit from mergersWeekly Risk Report & AI Forecast for Swing Trade Picks - newser.com
Will earnings trigger a reversal in Esperion Therapeutics Inc.2025 Year in Review & Reliable Entry Point Trade Alerts - newser.com
Why Esperion Therapeutics Inc. is moving todayMarket Risk Analysis & High Return Stock Watch Alerts - newser.com
Applying Elliott Wave Theory to Esperion Therapeutics Inc.Rate Cut & Low Drawdown Momentum Trade Ideas - newser.com
Can volume confirm reversal in Esperion Therapeutics Inc.2025 Market Overview & Safe Entry Point Identification - newser.com
How high can Esperion Therapeutics Inc. stock goJuly 2025 Decliners & Advanced Technical Analysis Signals - newser.com
Should you wait for a breakout in Esperion Therapeutics Inc.Market Trend Summary & Consistent Income Trade Ideas - newser.com
How to use Fibonacci retracement on Esperion Therapeutics Inc.Market Weekly Review & Weekly Stock Performance Updates - newser.com
Analyzing drawdowns of Esperion Therapeutics Inc. with statistical toolsProduct Launch & Real-Time Volume Analysis Alerts - newser.com
Why Esperion Therapeutics Inc. stock is favored by top institutionsMarket Growth Review & Free Community Consensus Stock Picks - newser.com
Identifying reversal signals in Esperion Therapeutics Inc.Earnings Beat & Target Return Focused Picks - newser.com
Update Recap: Why Esperion Therapeutics Inc. stock attracts high net worth investorsQuarterly Market Review & Consistent Income Trade Recommendations - nchmf.gov.vn
Will Esperion Therapeutics Inc. stock sustain high P E ratiosPortfolio Risk Report & Daily Stock Momentum Reports - nchmf.gov.vn
Is Esperion Therapeutics Inc. stock cheap at current valuationMarket Trend Review & Short-Term Trading Opportunity Alerts - nchmf.gov.vn
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up - The Globe and Mail
Esperion nominates ESP-2001 as preclinical candidate for PSC - BioWorld MedTech
Breakouts Watch: How Esperion Therapeutics Inc. stock compares to growth peersJuly 2025 Trends & Smart Money Movement Alerts - nchmf.gov.vn
Cantor Fitzgerald maintains Overweight rating on Esperion stock at $9 price target - Investing.com
How currency fluctuations impact Esperion Therapeutics Inc. stockBuy Signal & Fast Gain Swing Alerts - newser.com
Esperion Therapeutics Inc. (ESPR) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis - GlobeNewswire
IND filing goal 2026: Esperion nominates ESP-2001 as preclinical PSC candidate, $1B market - Stock Titan
Will Esperion Therapeutics Inc. stock gain from lower inflation2025 Support & Resistance & Real-Time Stock Movement Alerts - newser.com
Published on: 2025-10-15 12:04:18 - newser.com
How to integrate Esperion Therapeutics Inc. into portfolio analysis toolsJuly 2025 Trends & Real-Time Chart Breakout Alerts - newser.com
Esperion Therapeutics Inc. stock momentum explained2025 Geopolitical Influence & Low Risk High Reward Ideas - newser.com
How to use a screener to detect Esperion Therapeutics Inc. breakoutsPortfolio Gains Report & Proven Capital Preservation Methods - newser.com
What’s the recovery path for long term holders of Esperion Therapeutics Inc.Trend Reversal & Safe Investment Capital Preservation Plans - newser.com
Will breakout in Esperion Therapeutics Inc. lead to full recovery2025 Performance Recap & Risk Managed Trade Strategies - newser.com
5 Best Cheap Stocks Under $5 to Buy Right Now | Investing - Money US News.com
Why analysts remain bullish on Esperion Therapeutics Inc. stockQuarterly Profit Report & Fast Entry and Exit Trade Plans - newser.com
Esperion Therapeutics Inc Stock (ESPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):